Literature DB >> 1356649

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

L R Kelland1, G Abel.   

Abstract

Using the sulforhodamine B assay, we compared the cytotoxic properties of the novel microtubule agent taxol and the semi-synthetic related compound Taxotere in nine human ovarian-carcinoma cell lines, including three pairs of cell lines rendered resistant to cisplatin or carboplatin. In addition, the cytotoxicity of the commonly used anticancer drugs cisplatin and adriamycin and the topoisomerase II inhibitor etoposide was determined. The results of continuous drug exposure showed that taxol [mean concentration producing 50% growth inhibition (IC50), 1.1 x 10(-9) M; range, 2.8 x 10(-9)-5 x 10(-10) M and Taxotere (mean IC50, 5.1 x 10(-10) M; range, 7.2-3.3 x 10(-10) M) were greater than 1,000 times more cytotoxic than either cisplatin (mean IC50, 3.1 x 10(-6) M; P less than 0.05) or etoposide (mean IC50, 2.3 x 10(-6) M; P less than 0.05) and greater than 100 times more cytotoxic than Adriamycin (mean IC50, 6.9 x 10(-8) M; P less than 0.05). Taxotere was more cytotoxic than taxol; following continuous exposure, the mean difference across the cell lines was 2 orders of magnitude (range, 1.1-3.9 orders of magnitude for individual lines). Although this difference did not reach statistical significance for any individual cell line (P values ranged from 0.17 for HX/62 to 0.9 for OVCAR-3), when all IC50 values for the 96-h experiments were pooled, Taxotere was found to be significantly more potent than taxol (P = 0.05). Following 2 h exposure, the mean cytotoxicity of Taxotere was 3.9-fold greater than that of taxol across the nine lines (range, 0.75- to 10-fold; P less than 0.05 for the CH1 cell line; overall pooled IC50 data, P = 0.05). Although a 71-fold range of sensitivity to cisplatin was observed across the six parent cell lines (IC50 most resistant line/IC50 most sensitive line), this was largely abolished by treatment with taxol (5.6-fold range) and Taxotere (2.2-fold range). Following continuous exposure of the three pairs of lines exhibiting acquired resistance to platinum, no cross-resistance with either Taxotere or taxol was found (resistance factors, less than 1.5). In the 41M and 41McisR pair of lines, in which previous studies have shown resistance to be due to reduced platinum accumulation, taxol and Taxotere exhibited some collateral sensitivity (resistance factors, 0.69 and 0.66, respectively). Taxotere and, particularly, taxol showed a pronounced concentration times exposure duration (C x T) dependence as compared with cisplatin (P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356649     DOI: 10.1007/bf00685595

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

Review 1.  Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy.

Authors:  W P McGuire; E K Rowinsky
Journal:  Semin Oncol       Date:  1991-06       Impact factor: 4.929

Review 2.  Ovarian cancer: new clinical approaches.

Authors:  R F Ozols
Journal:  Cancer Treat Rev       Date:  1991-03       Impact factor: 12.111

3.  Estimates of the worldwide frequency of sixteen major cancers in 1980.

Authors:  D M Parkin; E Läärä; C S Muir
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

4.  Taxol: mechanisms of action and resistance.

Authors:  S B Horwitz; L Lothstein; J J Manfredi; W Mellado; J Parness; S N Roy; P B Schiff; L Sorbara; R Zeheb
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

5.  Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2' configurations.

Authors:  C S Swindell; N E Krauss; S B Horwitz; I Ringel
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

6.  Phase I clinical and pharmacokinetic study of taxol.

Authors:  P H Wiernik; E L Schwartz; J J Strauman; J P Dutcher; R B Lipton; E Paietta
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

7.  Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; B A Murrer; G Abel; C M Giandomenico; P Mistry; K R Harrap
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

8.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12

9.  Cisplatin/carboplatin cross-resistance in ovarian cancer.

Authors:  M E Gore; I Fryatt; E Wiltshaw; T Dawson; B A Robinson; A H Calvert
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

10.  Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division.

Authors:  F R Cabral
Journal:  J Cell Biol       Date:  1983-07       Impact factor: 10.539

View more
  31 in total

1.  Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

Authors:  A I Einzig; D Neuberg; S C Remick; D D Karp; P J O'Dwyer; J A Stewart; A B Benson
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

2.  Cancer cell surface induced peptide folding allows intracellular translocation of drug.

Authors:  Scott H Medina; Joel P Schneider
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

3.  Preclinical pharmacology of 1069C85, a novel tubulin binder.

Authors:  F I Raynaud; L R Kelland; M I Walton; I R Judson
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.

Authors:  L Vigano; A Locatelli; G Grasselli; L Gianni
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

6.  A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.

Authors:  Paul K Paik; Rachel K Kim; Linda Ahn; Andrew J Plodkowski; Ai Ni; Mark T A Donoghue; Philip Jonsson; Miguel Villalona-Calero; Kenneth Ng; Daniel McFarland; John J Fiore; Afsheen Iqbal; Juliana Eng; Mark G Kris; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2020-01-09       Impact factor: 12.531

7.  In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.

Authors:  Y Heike; M Takahashi; T Ohira; H Arioka; Y Funayama; K Nishio; H Ogasawara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.

Authors:  B T Hill; R D Whelan; S A Shellard; S McClean; L K Hosking
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 10.  Docetaxel: an alternative taxane in ovarian cancer.

Authors:  N Katsumata
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.